ADIL — Adial Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Brief: Adial Pharmaceuticals Signs An Exclusive Ad04 Collaboration Framework With Molteni Farmaceutici For Europe Which Anticipates Nearly $60 Million In Potential Royalties And Milestones Upon Execution Of A Definitive Agreement
Brief: Adial Pharmaceuticals Regains Full Compliance With Nasdaq Listing Requirement
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:58 AM
Adial Pharmaceuticals Q3 net loss beats expectations on lower R&D expenses
U.S. STOCKS ON THE MOVE-Hershey, Eli Lilly, energy stocks
U.S. STOCKS ON THE MOVE-Aqua Metals, Corbus Pharma, Micron
Adial rises on positive FDA feedback for its late-stage alcohol disorder drug study
Brief: Adial Pharma Provides Updates After FDA’s Favorable EOP2 Feedback on AD04 for Alcohol Use Disorder Treatment
Brief: Adial Pharmaceuticals Granted A 180 Calendar Day Extension By Nasdaq To Regain Compliance With The Minimum Bid Price Rule
Adial Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Adial Pharmaceuticals Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Adial Pharmaceuticals Completes Successful Eop2 FDA Meeting
Brief: Adial Pharmaceuticals Secures Agreements With Cambrex And Thermo Fisher Scientific
Adial Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Adial Pharmaceuticals Inc expected to post a loss of 49 cents a share - Earnings Preview
Adial Pharmaceuticals Inc expected to post a loss of 49 cents a share - Earnings Preview
Brief: Adial Pharmaceuticals Granted End Of Phase 2 Meeting From FDA
U.S. STOCKS ON THE MOVE-Maze Therapeutics, UFP Technologies, Itron